

1 **Title Page**

2
3 **Title:**

4 Identification of noninvasive and disease-specific biomarkers in hereditary
5 angioedema using urinary proteomics

6
7 Jianqiang Wu^{a#}, Xiaoyue Tang^{a#}, Xue Wang^{b#}, Peng Liu^{a#}, Nan Zhou^b, Zejian Zhang^a,
8 Yang Cao^b, Shuyang Zhang^{c*}, Yuxiang Zhi^{b*}

9
10 ^a Medical Research Center, State Key Laboratory of Complex Severe and Rare
11 Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical
12 Sciences & Peking Union Medical College, Beijing 100730, China;

13 ^b Department of Allergy & Clinical Immunology, National Clinical Research Center
14 for Immunologic Diseases, State Key Laboratory of Complex Severe and Rare
15 Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical
16 Sciences & Peking Union Medical College, Beijing 100730, China;

17 ^c State Key Laboratory of Complex Severe and Rare Diseases, Department of
18 Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical
19 Sciences & Peking Union Medical College, Beijing 100730, China.

20
21 ***Correspondence**

22 Yuxiang Zhi, Department of Allergy & Clinical Immunology, Peking Union Medical
23 College Hospital, No. 1 Shuaifuyuan, Beijing 100730, China. E-mail:
24 yuxiang_zhi@126.com;

25
26 Shuyang Zhang, State Key Laboratory of Complex Severe and Rare Diseases, Peking
27 Union Medical College Hospital, E-mail: shuyangzhang103@nrdrs.org

28
29 **Abstract**

30 **Background:** Hereditary angioedema (HAE) is a rare and potentially life-threatening
31 disease. Noninvasive and disease-specific biomarkers are needed for the early
32 diagnosis and clinical management of HAE.

33 **Objective:** We sought to apply untargeted proteomics profiling and targeted
34 proteomics validation to identify pathogenic mechanisms and candidate biomarkers of
35 HAE.

36 **Methods:** Data-independent acquisition (DIA)-based proteomics profiling was
37 performed in urine samples of HAE patients and healthy controls. Bioinformatics
38 analysis was used for functional annotation and pathway enrichment of differentially
39 expressed proteins. Furthermore, promising biomarker candidates were validated in
40 another independent clinical cohort using parallel reaction monitoring (PRM) targeted
41 proteomics quantification.

42 **Results:** Different urinary proteomics profiles were identified among type 1 HAE,
43 type 2 HAE and healthy controls. A total of 401 differentially expressed proteins were
44 identified between type 1 HAE and healthy controls. Bioinformatics analysis showed

45 that several biological processes and pathways were significantly enriched in HAE,
46 including complement and coagulation cascades, cell adhesion molecules, immune
47 response, proteolysis, and bradykinin catabolic process. Moreover, a promising
48 biomarker panel (C1-INH, KNG1 and EGF) were validated in another independent
49 clinical cohort. The area under the curve (AUC) value of this biomarker panel reached
50 0.910 for HAE diagnosis (sensitivity: 91.7, specificity: 88.9, $P < 0.001$).

51 **Conclusions:** This study describes the first application of a DIA-PRM workflow to
52 identify noninvasive and disease-specific biomarkers in HAE patients. These findings
53 will contribute to the pathogenesis research and biomarker discovery of HAE.

54

55 **Key Messages**

- 56 1. Different urinary proteomics profiles were identified among type 1 HAE, type 2
57 HAE and healthy controls.
- 58 2. Several biological processes and pathways were significantly enriched in HAE,
59 including complement and coagulation cascades, cell adhesion molecules,
60 immune response, proteolysis, and bradykinin catabolic process.
- 61 3. A urinary biomarker panel (C1-INH, KNG1, and EGF) could be a promising
62 noninvasive diagnostic tool for HAE.

63

64 **Key words:** hereditary angioedema; pathogenesis; biomarkers; proteomics; urine.

65

66 **Abbreviations Used:**

67 HAE, hereditary angioedema; HC, healthy control; LC-MS/MS, liquid
68 chromatography coupled with tandem mass spectrometry; DIA, data-independent
69 acquisition; PRM, parallel reaction monitoring; DEP, differentially expressed protein;
70 C1-INH or SERPING1, Protease C1 inhibitor; KNG1, Kininogen-1; EGF,
71 Pro-epidermal growth factor; CLU, Clusterin; ROC, receiver operator characteristics;
72 AUC, area under the curve.

73

74 **1. Introduction**

75 Hereditary angioedema (HAE) is clinically characterized by recurrent attacks of
76 subcutaneous and submucosal swelling, which involves the face, extremities, trunk,
77 genitalia, upper airways, and/or gastrointestinal tract¹. Classic HAE is caused by
78 mutation of the SERPING1 gene, which causes plasma protease C1 inhibitor (C1-INH)
79 deficiency². HAE with C1-INH deficiency can be subdivided into type 1 (decreased
80 plasma levels of C1-INH) and type 2 (normal levels but dysfunction of C1-INH).
81 Type 1 HAE accounts for the majority of HAE cases in China, and the percentage of
82 type 2 HAE cases in China is $< 5\%$. Other types of HAE due to defects in coagulation
83 factor XII, plasminogen, or angiotensin-1 have not been reported in China³.

84 HAE is a rare disease with an estimated prevalence of 1/50,000 and is often not
85 recognized⁴. As abdominal symptoms are common and important clinical features,
86 HAE is easily misdiagnosed, which can lead to unnecessary surgical procedures^{5,6}.
87 Furthermore, all HAE patients are at risk of a laryngeal attack, and more than 50%
88 have laryngeal attacks during their lifetime. Laryngeal edema-induced asphyxiation

89 without timely treatment is the main cause of death in HAE patients, and the mortality
90 rate ranges between 11% and 40%⁷⁻⁹. However, previous studies have reported that
91 the interval between the onset of symptoms and final diagnosis of HAE remains 8-13
92 years^{4,10,11}. Long diagnostic delay and inappropriate treatment will aggravate the
93 humanistic and economic burden for HAE patients¹². Therefore, early diagnosis and
94 disease evaluation are essential to improve the quality of life and clinical management
95 of HAE patients.

96 Biomarkers are measurable changes associated with physiological or
97 pathophysiological conditions^{13,14}. Without homeostatic control, urine accumulates
98 systematic changes in the body and has the potential to reflect small and early
99 pathological conditions¹⁴. Moreover, urine can be collected noninvasively and in
100 large volume. Thus, urine is an attractive sample source for biomarker research.
101 Proteomics is a powerful tool in biomarker discovery, exploration of pathogenesis,
102 and drug target identification¹⁵. With the rapid development of mass spectrometry
103 (MS) techniques, urinary proteomics has become a promising field in biomarker
104 discovery¹⁶. The urinary proteome is mainly composed of plasma proteins that pass
105 the glomerular barrier and proteins shed by cells within the urogenital system. Thus,
106 urinary proteomics could reflect both systemic and local conditions of the body.
107 Currently, in addition to its application in urological diseases¹⁷, urinary proteomics
108 has also been applied in cardiovascular diseases¹⁸, brain diseases¹⁹ and other diseases
109²⁰⁻²². Although urinary biomarkers have been investigated in many diseases, no urine
110 biomarkers are currently available for the diagnosis, disease monitoring and
111 therapeutic efficacy evaluation of HAE²³. Advances in high-throughput proteomics
112 technology may facilitate the discovery of promising noninvasive urine biomarkers of
113 HAE.

114 In this study, the data-independent acquisition (DIA)-based proteomics technique
115 was applied to explore the urinary protein profiling of HAE patients. Bioinformatics
116 analysis was performed to annotate the biofunctions and pathways of the differentially
117 expressed proteins (DEPs). Then, several promising biomarkers were further
118 validated in another independent clinical cohort using parallel reaction monitoring
119 (PRM)-based targeted proteomics. This study will provide a novel noninvasive
120 method for HAE diagnosis and will improve our understanding of the pathogenesis of
121 HAE.

122 123 **2. Methods**

124 **2.1 Patients and sample collection**

125 In the biomarker discovery phase, 20 adult HAE patients and 29 healthy controls
126 (HCs) were recruited from Peking Union Medical College Hospital (PUMCH) during
127 2020. Among these patients, 15 had type 1 HAE, and 5 had type 2 HAE. In the
128 biomarker validation phase, 24 other type 1 HAE patients and 18 HCs were recruited
129 from PUMCH during 2021. This study was conducted in accordance with the
130 Declaration of Helsinki (as revised in 2013). All HAE patients and HCs provided
131 written informed consent, and the Ethics Committee of PUMCH approved this study
132 (No. HS-2402).

133 Midstream first morning urine was collected from these subjects. Routine urine
134 test results were normal in all subjects. After collection, the urine samples were
135 centrifuged at $3,000 \times g$ for 20 min at $4\text{ }^{\circ}\text{C}$ to remove the cell debris, and the
136 supernatants were stored at $-80\text{ }^{\circ}\text{C}$ for further proteomics analysis.

137 **2.2 Sample preparation**

138 Samples were prepared using a filter-aided sample preparation method as previously
139 described²⁴. Briefly, samples were reduced with 20 mM dithiothreitol at $100\text{ }^{\circ}\text{C}$ for
140 10 min and alkylated with 50 mM iodoacetamide at room temperature for 30 min in
141 the dark. Then, urinary proteins were extracted from the samples by acetone
142 precipitation, and the pellets were resuspended with 20 mM Tris buffer. Then, 100 μg
143 of protein was loaded onto 30-kD filter devices (Pall, Port Washington, NY, USA) and
144 centrifuged at $14,000 \times g$ at $18\text{ }^{\circ}\text{C}$. After washing three times with 20 mM Tris buffer,
145 the samples were digested with trypsin at $37\text{ }^{\circ}\text{C}$ overnight. Finally, 2 μg of each
146 peptide sample was used for the subsequent LC-MS/MS analysis.

147 **2.3 DIA quantitative proteomic analysis**

148 LC-MS/MS analysis was performed by an Orbitrap QE HF mass spectrometer
149 coupled with an EASY-nLC 1200 UHPLC system (Thermo Fisher Scientific,
150 Waltham, MA, USA). Digested peptides were loaded onto a trap column ($75\text{ }\mu\text{m} \times 2$
151 cm , $3\text{ }\mu\text{m}$, C18, $100\text{ }\text{\AA}$). The peptides were separated on an analytical column ($75\text{ }\mu\text{m}$
152 $\times 500\text{ mm}$, Kyoto Monotech, Kyoto, Japan). The elution was set to 5–30% buffer B
153 (0.1% formic acid in 99.9% acetonitrile; flow rate of $0.3\text{ }\mu\text{l}/\text{min}$) for 60 min.
154 Moreover, an iRT kit (Biognosys, Schlieren, Switzerland) was added to all samples to
155 make retention time alignments among samples²⁵. The MS was set in DIA mode, and
156 the parameters were set as follows: the full scan was performed with a resolution of
157 120,000 and in the range of 350–1,500 m/z ; the cycle time was 3 s; the automatic gain
158 control (AGC) was $3e6$, and the injection time was under 100 ms; precursors were
159 selected by charge state screening with a +2 to +6 charge state; and the dynamic
160 exclusion duration was 10 s. During the DIA analysis, a mixed sample was inserted
161 after every ten samples for quality control (QC).

162 **2.4 PRM proteomics validation**

163 First, pooled peptide samples were subjected to LC-MS/MS analysis with six
164 technical replicates. Skyline software was used to build the spectrum library and
165 screen peptides for PRM analysis. For each targeted protein, two to five peptides were
166 selected using the following criteria: identified with q value $< 1\%$, completely
167 digested by trypsin, 8–18 amino acid residues, exclusion of the first 25 N-terminal
168 amino acids, and carbamidomethylation of cysteine as the fixed modification. Only
169 unique peptides of each protein were used for further PRM quantitation. The retention
170 time (RT) segment was set to $\pm 2\text{ min}$ for each targeted peptide, with its expected RT
171 in the center based on the pooled sample analysis.

172 To ensure data quality, a mixed sample was used as the quality control after every
173 10 samples to determine the stability of the instrument signal. To further ensure data
174 quality, an iRT standard was added to each sample, and the stability of the
175 chromatographic retention time was evaluated during the analysis. To reduce any
176 system bias, different groups of samples were analyzed in a random order.

177 **2.5 MS data processing and analysis**

178 All raw MS data in the DIA experiment were imported into Spectronaut software
179 (Biognosys AG, Switzerland) to generate the spectra library. The data were searched
180 against the UniProt human database appended with the iRT fusion protein sequence.
181 The parent ion tolerance was set at 10 ppm, and the fragment ion mass tolerance was
182 set to 0.05 Da. A maximum of two missed cleavage sites in the trypsin digestion was
183 allowed. Carbamidomethylation of cysteines was set as a fixed modification, and the
184 oxidation of methionine was considered a variable modification. Then, the DIA raw
185 files were searched against the self-built spectra library using Spectronaut Pulsar X.
186 The optimal XIC extraction window was determined according to the iRT calibration
187 strategy. The cross-run normalization was set to the local normalization based on the
188 local regression. Protein inference was performed using the implemented IDPicker
189 algorithm²⁶. The Q value was set to 0.01 for data filtering. The sum peak areas of the
190 respective fragment ions in MS₂ were used to quantify peptide intensities.

191 For the PRM validation, the MS data were processed with Skyline software. The
192 transition settings in Skyline were as follows: precursor charges, + 2 to + 5; ion types,
193 b, y, and p; the product ions from ion 3 to last ion – 1; ion match tolerance, 0.02 m/z;
194 the six most intense product ions were picked; and the variable “min dotp” was set to
195 0.7. The correct peaks were selected manually, and all of the peptide results were
196 exported. Total ion current (TIC) chromatograms were obtained for each sample in the
197 range of a +2 to +5 charge using Progenesis QI for Proteomics software. The mass
198 spectra data for each peptide were normalized with the TIC chromatogram of its
199 associated sample to correct for sample size and mass signal intensity errors. The
200 results for each peptide were quantitatively analyzed, and the identified differential
201 proteins were screened and compared with the DIA results.

202 **2.6 Bioinformatics and statistical analysis**

203 Functional annotation of differentially expressed proteins (DEPs) was performed
204 using DAVID database²⁷. The biological process, cellular component and molecular
205 function of DEPs were enriched. For Ingenuity Pathway Analysis (IPA), the SwissProt
206 accession numbers were uploaded to IPA software (Ingenuity Systems, CA, United
207 States). The biofunction and canonical pathway of DEPs were enriched. Pattern
208 recognition analysis (principal component analysis, PCA; orthogonal partial least
209 squares discriminant analysis, OPLS-DA) was conducted by SIMCA software
210 (version 15.0, Umetrics, Sweden). The statistical analysis was performed with
211 GraphPad Prism (version 8.0.2, GraphPad Software Inc., San Diego, California, USA).
212 Receiver operating characteristic (ROC) analysis was performed with the “Biomarker
213 discovery” module on the MetaAnalyst 5.0 website (<https://www.metaboanalyst.ca/>).

214

215 **3. Results**

216 **3.1 Clinical characteristics of subjects and study design**

217 A total of 44 HAE patients and 47 healthy controls were recruited in this study. In the
218 discovery phase, 20 newly diagnosed HAE patients (type 1: 15 patients; type 2: 5
219 patients) and 29 HCs were included for differential proteome discovery. HAE patients

220 and healthy controls were matched with age and sex. The average concentration of
221 plasma C1 inhibitors in type 1 HAE patients was significantly lower than that in type
222 2 HAE patients and HCs. In the validation stage, another independent clinical cohort
223 was recruited for biomarker validation, including 24 type 1 HAE patients and 18 HCs.

224 **3.2 DIA-based quantitative proteomics analysis**

225 In the biomarker discovery stage, urinary samples of 20 HAE patients and 29 HCs
226 were analyzed using the DIA quantitative proteomics method. A quality control
227 sample was used to assess the stability of the results. The correlations of the
228 quantified protein intensities of the QC samples showed satisfactory reproducibility
229 (R^2 -values: > 0.90). A total of 2562 protein groups were identified in the urine
230 samples, and 1716 reliable proteins quantified with at least two unique peptides were
231 used for further analysis.

232 This study compared the urine proteome profiles of HAE patients and HCs. The
233 results showed that there were significantly different urinary proteome profiles among
234 type 1 HAE, type 2 HAE and HCs (**Figure 1A**). Thus, type 2 HAE may involve
235 different pathophysiological processes compared with type 1 HAE. Interestingly,
236 urinary C1-INH expression was significantly higher in type 2 patients than in type 1
237 HAE patients (ratio = 2.76, $p < 0.001$). This result was consistent with the higher
238 expression of plasma C1-INH in type 2 HAE than in type 1 HAE. Moreover, the
239 OPLS-DA results showed that type 1 and type 2 HAE had significantly different
240 proteomic expression in urine samples, and these two disease subtypes could be
241 clearly separated from each other in the model (**Figure 1B**).

242 Because type 1 HAE accounts for more than 95% of all HAE cases in China, the
243 comparison of the urinary proteome between type 1 HAE and HCs was the focus of
244 this study. The PCA and OPLS-DA results showed that type 1 HAE can be
245 distinguished well from HCs based on the urinary protein pattern (**Figure 1 C-D**). A
246 total of 401 differential urinary proteins were identified (ratio >1.5, $p < 0.05$).
247 Interestingly, it was found that the abundance of urinary C1IN in type 1 HAE was
248 significantly lower than that of HCs (Ratio=2.79, $p < 0.0001$), suggesting that urinary
249 C1-INH could be a promising noninvasive diagnostic biomarker of type 1 HAE.

250 **3.3 Bioinformatics analysis of DEPs between type 1 HAE patients and HCs**

251 Functional annotation of the differential proteins between type 1 HAE patients and
252 HCs was performed using the DAVID database. In the biological process category,
253 cell adhesion, immune response, proteolysis, complement activation, blood
254 coagulation, innate immune response in mucosa, and bradykinin catabolic process
255 were significantly enriched (**Figure 2A**). In the molecular function category, antigen
256 binding, calcium ion binding, collagen binding, integrin binding, cadherin binding,
257 extracellular matrix structural constituent, signaling receptor activity, serine-type
258 endopeptidase inhibitor activity, and protease binding were significantly enriched
259 (**Figure 2B**).

260 To identify the major canonical pathways and diseases and biofunctions involved
261 with the differential urine proteins, IPA was used for enrichment analysis. It was

262 demonstrated that IL-15 signaling, B-cell receptor signaling, phagosome maturation,
263 complement system, acute phase response signaling, LXR/RXR activation,
264 coagulation system, and communication between immune cells were significantly
265 enriched (**Figure 2C**). Furthermore, in the disease and biofunction category, cell
266 movement of blood cells, degranulation of cells, activation of cells, complement
267 activation, angiogenesis, immune-mediated inflammatory disease, peripheral vascular
268 disease, movement of endothelial cells, and hereditary angioedema were significantly
269 enriched during HAE pathogenesis (**Figure 2D**). Interestingly, eight differential
270 proteins identified in our study were annotated in IPA to the disease item “hereditary
271 angioedema”, including angiotensin-converting enzyme (ACE), complement C1s
272 subcomponent (C1S), neutrophil elastase (ELANE), coagulation factor XII (F12),
273 kininogen-1 (KNG1), plasminogen (PLG), alpha-1-antitrypsin (SERPINA1), and
274 plasma protease C1 inhibitor (SERPING1 or C1IN). These results indicated that
275 urinary proteomics reflects the pathophysiological changes that occur in HAE.

276 **3.4 Association between the urinary proteome and clinical features**

277 These DEPs were then mapped into a coexpression network using STRING and
278 Cytoscape. The most significant cluster of the DEP coexpression network detected by
279 MCC (Cytoscape, CytoHubba) consisted of 10 hub proteins (CLU, C1-INH, CD59,
280 KNG1, C4A, EGF, RAC1, ACE, ANPEP and ENPEP) (**Figure 3A**). We also analyzed
281 the functions and networks of these hub proteins through GeneMANIA, and the main
282 functions of hub proteins were complement activation and coagulation (**Figure 3B**).
283 In addition, we selected several hub proteins to construct a biomarker combination,
284 and a biomarker panel consisting of plasma protease C1 inhibitor (SERPING1 or
285 C1-INH), pro-epidermal growth factor (EGF) and kininogen-1 (KNG1) had an ideal
286 diagnostic performance with an AUC of 0.956 (sensitivity: 100%, specificity: 82.8%)
287 (**Figure 4A**).

288 To demonstrate the clinical utility of our in-depth urinary proteomics analysis, we
289 further analyzed the association between the urinary proteome and disease severity.
290 As previously described²⁸, a severity scoring system was used to assess the disease
291 severity of HAE, which was mainly based on the onset age, edema location, clinical
292 manifestation, and long-term prophylaxis. Our results indicated that the expression
293 levels of two urine proteins (RAC1 and JAM3: junctional adhesion molecule C) were
294 positively correlated with the disease severity score, and the expression levels of six
295 urine proteins (QPCT, ANPEP, B4GALT1, MAN1A1, CLU, and EGF) were
296 negatively correlated with the disease severity score. In particular, CLU was the most
297 significant protein correlated with disease severity ($R=-0.758$, $p=0.001$), suggesting
298 that urinary clusterin has the potential to predict the disease severity of HAE (**Figure**
299 **4B**).

300 **3.5 PRM validation of promising biomarkers of HAE**

301 The biomarker panel was further validated in another independent cohort including
302 C1-INH, KNG1, and EGF. To ensure system stability and limit systemic bias during
303 targeted proteomic analysis, QC samples were injected before and after every 10

304 samples. By performing PCA on both the QC samples and individual urine samples,
305 the QC samples were closely clustered. The correlation map of QC samples also
306 showed that the QC samples were highly positively correlated with a Pearson
307 correlation coefficient above 0.95. These results demonstrated the stability of the MS
308 platform during proteomics analysis.

309 According to PRM targeted proteomics quantification, these three proteins showed
310 the same trend as those quantified in the DIA experiment and were significantly
311 decreased in type 1 HAE compared with HCs. Furthermore, the diagnostic
312 performance of this biomarker panel was evaluated using ROC analysis. The results
313 showed that this biomarker panel had good diagnostic performance with an AUC
314 value of 0.910 (sensitivity: 91.7%, specificity: 88.9%) (**Figure 5**).

315

316 **4. Discussion**

317 In this study, we performed DIA-based urinary proteomics profiling in HAE patients.
318 Several important biological processes and pathways were significantly enriched in
319 the pathogenesis of HAE. Furthermore, some disease-related biomarkers of HAE
320 were identified and further validated in another clinical cohort using PRM-based
321 targeted proteomics quantification. To our knowledge, this is the first application of
322 urinary proteomics analysis in HAE patients, and this study will provide a
323 noninvasive method for HAE diagnosis and improve the understanding of the
324 pathogenesis of HAE.

325 By DIA proteome profiling, it was found that there were significantly different
326 urinary proteome profiles among type 1 HAE patients, type 2 HAE patients and HCs.
327 Thus, although type 1 HAE and type 2 HAE share the deficiency of C1-INH, type 2
328 HAE may involve different pathophysiological processes compared with type 1 HAE.
329 As the sample size of type 2 HAE patients is relatively small, the conclusion needs
330 further confirmation. Interestingly, urinary C1-INH expression was significantly
331 higher in type 2 HAE patients than in type 1 HAE patients (ratio = 2.76, $p < 0.001$),
332 and urinary C1-INH in type 1 HAE patients was significantly lower than that in HCs
333 (ratio=2.79, $p < 0.0001$). The results suggested that urinary C1-INH is a promising
334 noninvasive and disease-specific biomarker for HAE.

335 HAE disease is characterized by recurrent episodes of mucosal edema. Currently,
336 the pathogenesis of HAE is not well understood. Previous studies have revealed that
337 classic HAE is caused by a deficiency of C1-INH, which can regulate proteases in
338 several pathways, including the complement, contact system, coagulation, and
339 fibrinolytic pathways. Moreover, deficiency of C1-INH and activation of the contact
340 system can lead to bradykinin overproduction. Bradykinin is the central mediator of
341 swelling in HAE, and activation of its receptor on vascular endothelial cells leads to
342 vascular instability, hyperpermeability, plasma extravasation, and resultant
343 angioedema^{29,30}. As type 1 HAE accounts for more than 95% of all HAE cases in
344 China¹¹, functional annotation of differential proteins between type 1 HAE patients
345 and HCs was the focus of this study. Our results showed that several biologic
346 processes were significantly changed in HAE, such as proteolysis, complement
347 activation, blood coagulation, innate immune response in mucosa, and bradykinin

348 catabolic process. Furthermore, complement activation, angiogenesis,
349 immune-mediated inflammatory disease, peripheral vascular disease, movement of
350 endothelial cells, and hereditary angioedema were significantly enriched in the
351 disease and biofunction category. These bioinformatics results were closely related to
352 the pathophysiology of HAE and will lead to a better understanding of the
353 pathogenesis of HAE. Moreover, eight differential urinary proteins identified in our
354 study were annotated in IPA to the disease item “hereditary angioedema”. These
355 results indicated that urinary proteomics reflects the pathophysiological changes that
356 occur in HAE and may serve as a noninvasive biomarker source of HAE.

357 Because the sensitivity and specificity of a single biomarker are often inadequate,
358 the establishment of a biomarker panel is preferred. In this study, we selected several
359 hub proteins in the coexpression analysis to construct a biomarker panel for HAE
360 diagnosis. In the biomarker discovery cohort, a combination of three urinary proteins
361 (C1-INH + KNG1 + EGF) showed good performance for the diagnosis of HAE with
362 an AUC of 0.956. Moreover, this biomarker panel was successfully validated in
363 another independent clinical cohort with an AUC of 0.910, suggesting its good
364 clinical application prospects. C1-INH has serine-type endopeptidase inhibitor
365 activity and plays a crucial role in regulating important physiological pathways,
366 including complement activation, blood coagulation, fibrinolysis, innate immune
367 response and the generation of kinins. Currently, plasma C1-INH is a crucial disease
368 biomarker of HAE in clinical practice. Furthermore, kininogen is an inhibitor of thiol
369 protease. HMW-kininogen plays an important role in blood coagulation, and
370 bradykinin is released from HMW-kininogen as a result of activation of the contact
371 system³¹. A recent study reported that mutations in the KNG1 gene can cause a novel
372 type of HAE³². In addition, EGF has rarely been reported in HAE, but EGF can
373 regulate endothelial cell migration and proliferation. Thus, EGF may affect vascular
374 endothelial cell organization and plasma extravasation. The role of EGF in the
375 pathogenesis of HAE requires further research. In addition, we observed that urinary
376 CLU was significantly correlated with the disease severity of HAE ($R=-0.758$,
377 $p=0.001$). CLU is a regulator of the complement terminal pathway and can sequester
378 terminal complement components C7-C9 to block the assembly of the membrane
379 attack complex (MAC)³³. Thus, urinary CLU is a potential biomarker to predict the
380 prognosis of HAE.

381 HAE is a rare and potentially life-threatening disease. This disease is often
382 misdiagnosed for years owing to the general lack of knowledge and its nonspecific
383 manifestations. This condition leads to HAE patients not only suffering from the
384 effects of the disease itself but also from ineffective treatment and needless invasive
385 diagnostic and therapeutic medical procedures. To minimize the suffering and
386 improve quality of life, it is necessary to discover noninvasive and specific
387 biomarkers for HAE. In this study, using DIA- and PRM-based proteomics
388 quantification, we identified several promising biomarkers for HAE. Moreover,
389 significant biological processes and pathways were identified in this study, which
390 would provide references for further investigations on the pathogenesis of HAE. As
391 HAE is a rare disease, the limitation of this study is that it was performed at a single

392 center with a relatively small sample size. In the future, multicenter and prospective
393 clinical validation is needed to verify the clinical application of these biomarkers.

394

395 **5. Conclusion**

396 To our knowledge, this is the first application of urinary proteomics in HAE patients.
397 Our results showed that the urinary proteome can reflect the pathophysiological
398 changes of HAE and has the potential to serve as a noninvasive biomarker source for
399 the diagnosis and clinical management of HAE. A biomarker panel (C1HN, KNG1,
400 and EGF) showed good performance for the diagnosis of HAE. This study provides a
401 novel noninvasive method for HAE diagnosis and enhances our understanding of the
402 pathogenesis of HAE.

403

404 **Acknowledgements**

405 This study was supported by grants from the National Key Research and
406 Development Program of China (No. 2016YFC0901501), the National Natural
407 Science Foundation of China (No. 81472870), the CAMS Innovation Fund for
408 Medical Sciences (CIFMS 2021-1-I2M-003) and Youth Science Fund of Peking
409 Union Medical College Hospital (pumch201912152). The funding organization was
410 not involved in the collection, management, or analysis of the data; preparation or
411 approval of the manuscript; or decision to submit the manuscript for publication.

412 **Conflict of interest**

413 The authors have no conflicts of interest relevant to this article to disclose.

414 **Author Contributions:**

415 JW, YZ and SZ: proposed and designed this study. JW, XT, XW, PL, NZ, ZZ and YC:
416 collected the samples and performed the experiments. JW, XT, LP and XW: data
417 analysis. JW and YZ: wrote and revised the manuscript. All authors have accepted
418 responsibility for the entire content of this manuscript and approved submission.

419

420 **References**

- 421 1. Busse PJ, Christiansen SC. Hereditary Angioedema. *N Engl J Med* 2020; 382:1136-48.
- 422 2. Xu YY, Gu JQ, Zhi YX. Hereditary angioedema caused by a premature stop codon
423 mutation in the SERPING1 gene. *Clin Transl Allergy* 2020; 10:53.
- 424 3. Liu S, Xu Y, Liu Y, Zhi Y. Hereditary angioedema: a Chinese perspective. *Eur J Dermatol*
425 2019; 29:14-20.
- 426 4. Zanichelli A, Magerl M, Longhurst H, Fabien V, Maurer M. Hereditary angioedema with
427 C1 inhibitor deficiency: delay in diagnosis in Europe. *Allergy Asthma Clin Immunol* 2013;
428 9:29.
- 429 5. Cao Y, Liu S, Zhi Y. Recurrent and acute abdominal pain as the main clinical
430 manifestation in patients with hereditary angioedema. *Allergy Asthma Proc* 2021;
431 42:131-5.
- 432 6. Hahn J, Hoess A, Friedrich DT, Mayer B, Schauf L, Hoffmann TK, et al. Unnecessary
433 abdominal interventions in patients with hereditary angioedema. *J Dtsch Dermatol Ges*
434 2018; 16:1443-9.
- 435 7. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary

- 436 angioedema due to C1-INH deficiency. *J Allergy Clin Immunol* 2012; 130:692-7.
- 437 8. Xu YY, Zhi YX, Liu RL, Craig T, Zhang HY. Upper airway edema in 43 patients with
438 hereditary angioedema. *Ann Allergy Asthma Immunol* 2014; 112:539-44 e1.
- 439 9. Bork K, Siedlecki K, Bosch S, Schopf RE, Kreuz W. Asphyxiation by laryngeal edema in
440 patients with hereditary angioedema. *Mayo Clin Proc* 2000; 75:349-54.
- 441 10. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US
442 HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary
443 Angioedema. *J Allergy Clin Immunol Pract* 2021; 9:132-50 e3.
- 444 11. Xu YY, Jiang Y, Zhi YX, Yin J, Wang LL, Wen LP, et al. Clinical features of hereditary
445 angioedema in Chinese patients: new findings and differences from other populations.
446 *Eur J Dermatol* 2013; 23:500-4.
- 447 12. Liu S, Wang X, Xu Y, Xu Q, Zhi Y. Risk factors for diagnostic delay in Chinese patients
448 with hereditary angioedema. *Allergy Asthma Proc* 2019; 40:343-9.
- 449 13. Gao Y. Urine-an untapped goldmine for biomarker discovery? *Sci China Life Sci* 2013;
450 56:1145-6.
- 451 14. Wu J, Gao Y. Physiological conditions can be reflected in human urine proteome and
452 metabolome. *Expert Rev Proteomics* 2015; 12:623-36.
- 453 15. Wu J, Wang W, Chen Z, Xu F, Zheng Y. Proteomics applications in biomarker discovery
454 and pathogenesis for abdominal aortic aneurysm. *Expert Rev Proteomics* 2021:1-10.
- 455 16. Zhao M, Li M, Yang Y, Guo Z, Sun Y, Shao C, et al. A comprehensive analysis and
456 annotation of human normal urinary proteome. *Sci Rep* 2017; 7:3024.
- 457 17. Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, et al. Early
458 detection of diabetic kidney disease by urinary proteomics and subsequent intervention
459 with spironolactone to delay progression (PRIORITY): a prospective observational study
460 and embedded randomised placebo-controlled trial. *Lancet Diabetes Endocrinol* 2020;
461 8:301-12.
- 462 18. Wang W, Wu J, Liu P, Tang X, Pang H, Xie T, et al. Urinary Proteomics Identifying Novel
463 Biomarkers for the Diagnosis and Phenotyping of Carotid Artery Stenosis. *Front Mol
464 Biosci* 2021; 8:714706.
- 465 19. Wu J, Zhang J, Wei J, Zhao Y, Gao Y. Urinary biomarker discovery in gliomas using mass
466 spectrometry-based clinical proteomics. *Chin Neurosurg J* 2020; 6:11.
- 467 20. Tian W, Zhang N, Jin R, Feng Y, Wang S, Gao S, et al. Immune suppression in the early
468 stage of COVID-19 disease. *Nat Commun* 2020; 11:5859.
- 469 21. Virreira Winter S, Karayel O, Strauss MT, Padmanabhan S, Surface M, Merchant K, et al.
470 Urinary proteome profiling for stratifying patients with familial Parkinson's disease.
471 *EMBO Mol Med* 2021; 13:e13257.
- 472 22. Sun Y, Guo Z, Liu X, Yang L, Jing Z, Cai M, et al. Noninvasive urinary protein signatures
473 associated with colorectal cancer diagnosis and metastasis. *Nat Commun* 2022; 13:2757.
- 474 23. Porebski G, Kwitniewski M, Reshef A. Biomarkers in Hereditary Angioedema. *Clin Rev
475 Allergy Immunol* 2021; 60:404-15.
- 476 24. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method
477 for proteome analysis. *Nat Methods* 2009; 6:359-62.
- 478 25. Escher C, Reiter L, MacLean B, Ossola R, Herzog F, Chilton J, et al. Using iRT, a
479 normalized retention time for more targeted measurement of peptides. *Proteomics* 2012;

- 480 12:1111-21.
- 481 26. Zhang B, Chambers MC, Tabb DL. Proteomic parsimony through bipartite graph analysis
482 improves accuracy and transparency. *J Proteome Res* 2007; 6:3549-57.
- 483 27. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large
484 gene lists using DAVID bioinformatics resources. *Nat Protoc* 2009; 4:44-57.
- 485 28. Bygum A, Fagerberg CR, Ponard D, Monnier N, Lunardi J, Drouet C. Mutational
486 spectrum and phenotypes in Danish families with hereditary angioedema because of C1
487 inhibitor deficiency. *Allergy* 2011; 66:76-84.
- 488 29. Porebski G, Kwitniewski M, Reshef A. Biomarkers in Hereditary Angioedema. *Clin Rev*
489 *Allergy Immunol* 2021; 60:404-15
- 490 30. Zuraw BL, Christiansen SC. HAE Pathophysiology and Underlying Mechanisms. *Clin*
491 *Rev Allergy Immunol* 2016; 51:216-29.
- 492 31. Kaplan AP, Joseph K, Ghebrehiwet B. The complex role of kininogens in hereditary
493 angioedema. *Front Allergy* 2022; 3:952753.
- 494 32. Bork K, Wulff K, Rossmann H, Steinmuller-Magin L, Braenne I, Witzke G, et al.
495 Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing
496 the N-terminal cleavage site of bradykinin. *Allergy* 2019; 74:2479-81.
- 497 33. Morgan BP. Complement in the pathogenesis of Alzheimer's disease. *Semin*
498 *Immunopathol* 2018; 40:113-24.

499

500 **Figure Legends**

501 **Figure 1. Urinary proteome profiling of type 1 HAE, type 2 HAE and HCs.**

502 (A) OPLS-DA of type 1 HAE, type 2 HAE, and healthy controls; (B) OPLS-DA of
503 type 1 HAE and type 2 HAE; (C-D) PCA and OPLS-DA of type 1 HAE and HCs.

504

505 **Figure 2. Bioinformatics analysis of DEPs between type 1 HAE patients and HCs.**

506 (A-B) Biological processes and molecular functions annotated in the DAVID database;
507 (C-D) canonical pathway and disease & biofunction annotation of DEPs in IPA.

508

509 **Figure 3. Coexpression network analysis of potential biomarkers of HAE.**

510 (A) Ten hub proteins of the coexpression network; (B) the major functions of the hub
511 proteins.

512





513 **Figure 4. Diagnostic performance and clinical association of candidate**





514 **biomarkers.** (A) The ROC analysis result of a biomarker panel (EGF+C1-INH+
515 KNG1) in DIA; (B) correlation of the urinary CLU level and disease severity score of
516 HAE.



517


518 **Figure 5. Targeted validation of promising biomarkers in another cohort.**

519 (A-C) DIA and PRM proteome quantification of C1IN, KNG1 and EGF in urine samples; (D)
520 ROC analysis of the biomarker panel (C1IN+ KNG1+EGF) in PRM.





A**B**

A**B**